Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.

Nature communications - 20 Aug 2020

Hakimi A Ari, Attalla Kyrollis, DiNatale Renzo G, Ostrovnaya Irina, Flynn Jessica, Blum Kyle A, Ged Yasser, Hoen Douglas, Kendall Sviatoslav M, Reznik Ed, Bowman Anita, Hwee Jason, Fong Christopher J, Kuo Fengshen, Voss Martin H, Chan Timothy A, Motzer Robert J

Abstract excerpt

There is conflicting data regarding the role of PBAF complex mutations and response to immune checkpoint blockade (ICB) therapy in clear cell renal cell carcinoma (ccRCC) and other solid tumors. We assess the prevalence of PBAF complex mutations from two large cohorts including the pan-cancer TCGA project (n = 10,359) and the MSK-IMPACT pan-cancer immunotherapy cohort (n = 3700). Across both cohorts, PBAF complex...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Chromosomal Proteins, Non-Histone

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cohort Studies

Share to DNA-Binding Proteins

Share to Gene Expression Regulation, Neoplastic

Share to Immunotherapy

Share to Kaplan-Meier Estimate

Share to Kidney Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32820162
DOI: 10.1038/s41467-020-17965-0
PMCID: PMC7441387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response.PMID 32820162Read ↗

<i>PBRM1</i> loss-of-function mutations and response to immune checkpoint blockade in clear cell renal cell carcinomaSemantic proximity Read ↗

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.Semantic proximity Read ↗

Mutational Analysis of PBRM1 and Significance of PBRM1 Mutation in Anti-PD-1 Immunotherapy of Clear Cell Renal Cell CarcinomaSemantic proximity Read ↗

PBRM1 mutation as a predictive biomarker for immunotherapy in multiple cancersSemantic proximity Read ↗

[Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].Semantic proximity Read ↗

Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinomaSemantic proximity Read ↗

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.Semantic proximity Read ↗

Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.Semantic proximity Read ↗

Molecular determinants of response to PD-L1 blockade across tumor types.Semantic proximity Read ↗

NDC80 status pinpoints mitotic kinase inhibitors as emerging therapeutic options in clear cell renal cell carcinomaSemantic proximity Read ↗

PBRM1 mutation and preliminary response to immune checkpoint blockade treatment in non-small cell lung cancerSemantic proximity Read ↗

NF1/2 mutations predict favorable benefit from immune checkpoint inhibitor-based therapies over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.